Three Billion Reports 4.6 Billion KRW in First-Half Sales, Up 107% Year-on-Year

Strong Signal for Achieving Annual Targets

Three Billion, an artificial intelligence (AI)-based rare disease diagnostics company, announced on August 14 that its sales for the first half of this year reached 4.6 billion KRW, representing a 107% increase compared to the same period last year.

Three Billion

This performance amounts to approximately 80% of last year's total annual sales of 5.8 billion KRW. The company is also expected to achieve its annual sales target of 9 billion KRW, which was set at the time of its IPO.

Three Billion's sales in the second quarter of this year were 2.6 billion KRW, a 101% increase year-on-year and a 29.3% increase compared to the previous quarter. The operating loss for the second quarter was 1.6 billion KRW, which is an 18.9% decrease from the previous quarter.

The main driver of growth in the second quarter was rare disease diagnostic genetic testing based on whole exome sequencing (WES) and whole genome sequencing (WGS). Sales from these services increased by 50.5% compared to the previous quarter, and the proportion of overseas sales during the same period reached 72%, highlighting the company's strong global expansion.

Kim Changwon, CEO of Three Billion, stated, "The first half of this year was marked by stable growth in our core AI-based diagnostic services and the expansion of our global network." He added, "Building on our performance, which doubled compared to the same period last year, we will accelerate global sales growth in the second half, achieve our annual targets, and demonstrate our growth potential with even greater results."